Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Pharmacological Actions of Multi-Target-Directed Evodiamine

Hui Yu, Hongwei Jin, Wuzhuang Gong and 2 more

Molecules · 2013 · Review · CC BY

doi:10.3390/molecules18021826

Abstract

Evodiamine, a naturally occurring indole alkaloid, is one of the main bioactive ingredients of Evodiae fructus. With respect to the pharmacological actions of evodiamine, more attention has been paid to beneficial effects in insults involving cancer, obesity, nociception, inflammation, cardiovascular diseases, Alzheimer's disease, infectious diseases and themoregulative effects. Evodiamine has evolved a superior ability to bind various proteins, so we also argue that it is good starting point for multi-target drugs. This review is primarily addressed to the description of the recent advances in the biological activity studies of evodiamine, with a focus on pharmacological mechanism. The present review also includes the pharmacokinetics and the detailed exploration of target-binding properties of evodiamine in an attempt to provide a direction for further multi-target drug design.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Many common diseases like diabetes, cardiovascular disease, and cancer are caused by a set of several factors, such as physiological, pathological, environmental, and lifestyle. In the past, the main effort was aimed at developing highly specific molecules acting on single targets. Now, there is a general agreement that molecules interfering simultaneously with multiple targets might be more effective than single target agents. Moreover, using such a multi-targeted approach could theoretically permit low-dose administration of active agents therefore reducing the potential undesired events by providing synergistic or additive preventive effects. Chinese herbal medicines are attracting intensive attention because of their history of reliable therapeutic efficacy for the prevention and treatment of various human diseases for thousands of years. Phytochemicals from medicinal plants play a vital role in treating diseases by influencing the function of a number of diverse targets. Therefore, Chinese herbal medicines are becoming important resources for designing multi-target bioactive molecules. Accordingly, it is worth noting that genomic, proteomic, and computational approaches have been explored to identify the molecular targets of natural products. Over the past decade, more and more molecular targets of certain natural herbal product have been proposed, which is helpful for current multi-target drug discovery. For example, the Zhang research group investigated the therapeutic mechanisms of astragaloside IV extracted from Astragalus membranaceus Bunge, a medicinal herb used for cardiovascular diseases. They identified a total of 39 putative targets of astragaloside IV, implicating that the therapeutic effects of astragaloside IV are based upon a combination of blocking calcium influx, vasodilation, anti-thrombosis, anti-oxidation, anti-inflammation and immune regulation.

The fruit of “Wu-Zhu-Yu” (Evodiae fructus; Evodia rutaecarpa Benth., Rutaceae) is one of the most popular and multi-purpose herbs traditionally used in China for the treatment of headaches, abdominal pain, difficult menstruation, vomiting, diarrhea, and other diseases. Phytochemical studies have shown the presence of evodiamine (Figure 1), which is an indole alkaloid found in large amounts in the Chinese medicine evodia.

Growing evidence demonstrates that evodiamine represents an important compound possessing a wide spectrum of biological activities, suggesting that it might interact with a number of diverse targets to carry out its therapeutic effects. The broad spectrum of medicinal properties associated with this compound has encouraged medicinal chemists to design and synthesize a large number of novel therapeutic agents. Several analogues exhibit significant anti-tumour, anti-microbial, and anti-inflammatory activities. For this reason evodiamine is an object of continuously growing interest amongst the scientists. With the characterization of the molecular targets for evodiamine, evodiamine can be used as a promising scaffold for development of a novel class of multi-target-directed compounds, which can be beneficial for cancer or inflammatory treatment. This review attempts to summarize the recent researches on evodiamine focusing on biological activity and mechanism of action. Moreover, target-binding properties and bioavailability of evodiamine were also highlighted.

2.1. Anti-Inflammatory Activity

An appreciable amount of research has reported on the potential anti-inflammatory properties and the possible underlying mechanisms of action of evodiamine. Nitric oxide (NO) is a highly reactive molecule produced from the amino acid arginine by the enzyme NO synthase (NOS). Inappropriate, excessive production of NO is largely responsible for pathogenesis of various inflammatory diseases. Chiou et al., examined the possible anti-inflammatory effects of evodiamine by assessing its effects on NO production in cultured murine macrophage-like cell line RAW 264.7. Their results indicated that evodiamine inhibited NO production by interfering with the interferon-gamma (IFN-γ)-initiated signaling events. Ko et al., also found that anti-inflammatory activities of evodiamine could be partially explained by its potentials for inhibiting inducible nitric oxide synthase (iNOS)-dependent NO production in activated inflammatory cells. In addition, evodiamine was found to inhibit the action of nuclear factor kappa B (NF-κB) and the transcription of cyclo-oxygenase-2 (COX-2). Liu et al. recently demonstrated that evodiamine inhibited COX-2 expression and hypoxia-inducible factor 1α (HIF-1α) accumulation via dephosphorylation of the serine/threonine protein kinase B (PKB/Akt) and the 70 kDa ribosomal S6 kinase (p70S6k), providing evidence for a novel mechanism underlying its anti-inflammatory activity. Moreover, evodiamine has strong inhibitory effects on the synthesis of prostaglandin E2 (PGE2), which is the principal pro-inflammatory prostanoid and contributes to one of the key features of inflammation. These results provide a scientific rationale for the anti-inflammatory use of evodiamine. The central role of evodiamine in the regulation of inflammatory is summarized in Figure 2.

2.2. Anti-Cancer Activity

Evodiamine has been shown to exhibit anti-tumor properties by inhibiting proliferation of various cancer cell lines, including cervical cancer cells, colon cancer cells, lung cancer cells, melanoma cells, leukemic T-lymphocyte cells, prostate cancer cells and breast cancer cells. One well-known manner of suppressing proliferation rates by evodiamine involves cell cycle progression arrest (G2/M phase) via activation of Cdc2/cyclin B. In addition, evodiamine induced apoptosis of a variety of tumor cell lines through several pathways. Takada et al. found that evodiamine exhibited apoptotic activity by modulating NF-κB activation, which leads to inhibition of NF-κB-regulated gene products such as Cyclin D1, X chromosome-linked IAP (XIAP), Bcl-2, and Bcl-Xl. Other studies further revealed that evodiamine increased the expression of the apoptosis inducer Bax and decreased that of the apoptosis suppressor Bcl-2, and then induced apoptosis through the caspase pathway. Reactive oxygen species (ROS) and NO generations were also found to exhibit regulatory effects on functions of p53, p21, protein tyrosine kinase (PTK) and other signaling proteins involved in evodiamine-induced apoptosis. PI3K/Akt and extracellular signal-regulated kinases (ERKs) signaling pathways were also found to exhibit essential roles in the responses of tumor cells apoptosis induced by evodiamine. Besides its anti-proliferative and anti-apoptotic effects, the effective inhibition of tumor invasion and metastasis are additional mechanisms by which evodiamine may communicate to halt the cancerous process. Moreover, evodiamine has recently been identified as a dual catalytic inhibitor of topoisomerases I and II. Figure 3 showed the potential anti-tumor properties and the possible underlying mechanisms of evodiamine.

2.3. Anti-Obesity Activity

Evodiamine has excellent potential as an agent to prevent obesity. Kobayashi et al. found that evodiamine appeared to prevent obesity and reduce body fat. The major mechanism eliciting the effect was postulated to be enhancement of uncoupling protein-1 (UCP1) thermogenesis through β3-adrenergic stimulation in brown adipose tissue (BAT). Shi et al. reported that intragastric administration of evodiamine suppressed the neuropeptide Y (NPY) mRNA and peptide levels in the arcuate nucleus (ARC) of the hypothalamus, which might be one of the mechanisms by which evodiamine exerted its fat loss effects. In addition, Wang et al. reported that evodiamine inhibited adipogenesis by simulating the ERK/MAPK signaling pathway, which modulated the expression of the adipocyte specific transcription factors and Akt signaling. They also found that evodiamine improved leptin resistance and insulin sensitivity in the mice. Moreover, evodiamine inhibited both gastric emptying and gastrointestinal transit, whereas increased the plasma concentration of cholecystokinin (CCK) in a dose-dependent manner, which plays a key role in regulation of digestion and appetite.

2.4. Anti-Cardiovascula Disease Activity

Evodiamine showed a beneficial effect on cardiovascular diseases as reported previously. Chiou et al., found that evodiamine had a vasodilatory effect in rat isolated mesenteric arteries and the effect was endothelium dependent. Evodiamine also demonstrated significant diuretic effect due to the inhibition of aldosterone release, which can control blood volume. In addition, several studies showed that evodiamine produced transient positive inotropic and chronotropic effects on the guinea-pig isolated atria. Previous investigations also indicated that evodiamine possessed a protective effect of cardiac anaphylactic injury by stimulation of calcitonin gene-related peptide (CGRP) release. Similarly, evodiamine exerted protection against myocardial ischemia-reperfusion injury in rats by activation of vanilloid receptors to stimulate the CGRP release. Moreover, evodiamine inhibited LIGHT-induced production of chemokine receptor (CCR) 1, CCR2, intracellular adhesion molecule 1 (ICAM-1), the phosphorylation of ERKs and p38 MAPK via decreasing ROS production and NADPH oxidase activation, implicating that evodiamine has the potential for use as anti-atherosclerosis agents.

2.5. Anti-Alzheimer’s Disease Activity

Alzheimer’s disease (AD) is a progressive, irreversible brain disease caused by degeneration of synapses and death of neurons, resulting in cognitive, memory and behavioral impairments. It is reported that a variety of biologically active constituents isolated from traditional Chinese herbs can significantly reduce the risk of AD. Recently, the effect and the possible mechanisms of action of evodiamine in AD mouse models were investigated. Evodiamine was reported to improve the cognitive abilities in the transgenic models of AD. Further investigations demonstrated that evodiamine treatment increased glucose uptake in brain tissue. The results also indicated that evodiamine inhibited the expression of COX-2 and inflammatory cytokines in AD mouse models, such as IL-1β, IL-6, and TNF-α. However, evodiamine had no effect on amyloid beta-peptide (Aβ) deposition. Therefore, the effect of evodiamine on improvement of behavior in AD mouse models was likely mediated through the inhibition of the inflammatory process. Moreover, previous investigations indicated that dehydroevodiamine, an evodiamine analogue also demonstrated significant effect on AD. The chemical structure of dehydroevodiamine has been used as a basis in the clinical development of novel cholinesterase inhibitors.

2.6. Anti-Microbial Activity

Anti-microbial agents for the treatment of infections caused by bacteria, fungi and protozoa are different from the pharmacodynamic agents that affected the physiological, biochemical, or immunological function of host. The increase in number of antibiotic-resistant pathogenic bacteria has stimulated research on the development and application of new antimicrobial agents. Some compounds isolated from Evodia rutaecarpa were found to act as new anti-infectious agents, such as 3-dimethylallyl-4-methoxy-2-quinolone, 1-methyl-2-pentadecyl-4(1H)-quinolone, evocarpine, dihydro-evocarpine and 1-methyl-2-[(Z)-8-tridecenyl]-4-(1H)-quinolone. Recently, Chiou et al. found that the compound evodiamine was effective in suppressing H1N1-induced chemokines production and blocking chemokine-attracted leukocytes recruitment, implicating potential in influenza virus infection-related inflammatory disorders. Our group also found that evodiamine was capable of deactivation of E. coli and can be used as a natural antimicrobial agent. These results have not been reported yet.

2.7. Other Activities

It is well known that transient receptor potential cation channel subfamily V member 1 (TRPV1) plays a fundamental role in modulation of pain. Some studies demonstrated that evodiamine exerted the analgesic effects due to its vanilloid receptor agonistic activities. Evodiamine possesses many other biological functions, such as thermoregulatory effect, antianoxic action, dermatological applications, bronchoconstrictive action, and hormones secretion.

3. Protein-Ligand Interaction

Identification of molecular targets of evodiamine is an enormous opportunity for modern pharmacology. Up to data, three proteins are believed to be direct targets of evodiamine, including TRPV1, the aryl hydrocarbon receptor (AhR), and topoisomerases I and II. These proteins seem to be important in inflammation, cancer and other diseases. In fact, compounds which can regulate multiple targets may have superior utility over single-target drugs. For example, Guerrant et al. synthesized dual-acting histone deacetylase and topoisomerase II inhibitors, which potently inhibit the proliferation of representative cancer cell lines. Recently, the structures of several complexes of evodiamine with its targets have been elucidated. Investigations of the interaction between evodiamine and various targets provided detailed information regarding the structural features required for binding, which can be exploited in future multi-target drug discovery strategies.

3.1. TRPV1

TRPV1, a member of the transient receptor potential superfamily, is activated by protons, heat, endogenous substances and natural ligands such as capsaicin, resiniferatoxin, and evodiamine. The receptor participated in a wide variety of pathological and physiological processes, suggesting that regulation of this receptor activation should have considerable therapeutic utility. TRPV1 has been linked to processes mediating inflammation, cancer, cardiovascular diseases, obesity, skin diseases, and neuropathic pain. TRPV1 ligands have attracted much attention as promising drug candidates to block related pathological states associated with this receptor. Evodiamine is a vanilloid receptor agonist, and thus represents a new potential class of lead molecules for new analgesics development. Recently, our group investigated the precise interaction between evodiamine and TRPV1 using homology modeling, molecular docking, dynamics simulation and pharmacophore modeling methods. Our results showed that the ring 1 of evodiamine pointed toward Tyr511, establishing a hydrophobic interaction. The ring 5 of evodiamine pointed toward Tyr555, forming aromatic π-π interactions. In addition, evodiamine made two H-bonds between carbonyl oxygen and amino group of Lys571 and between indol nitrogen and backbone of Ile569. Pharmacophore modeling provided further evidence for the validity of the docking studies. This study identified the structural determinants required for the interaction between TRPV1 and evodiamine, and gave new suggestions for the rational design of novel TRPV1 ligands. The biological activity experiment showed that evodiamine bound to rat TRPV1 with a Ki of 5.95 ± 0.87 microM, and yielded an EC50 value of 856 ± 43 nM. Figure 4 showed the predicted binding mode of evodiamine in the active site of vanilloid receptor TRPV1.

3.2. DNA Topoisomerases

DNA topoisomerases (I and II) are complex enzymes, which control the topological state of DNA throughout breaking and rejoining of DNA strands. Topoisomerases are involved in various DNA-related cellular processes, such as replication, transcription, recombination, chromatin condensation and daughter chromatides partitioning. A lot of new data concerning basic features of the different types of topoisomerases was published. Since the structure and function were well characterized, topoisomerases have been shown to have a potential use for drug design. It is well known that the inhibitors of DNA topoisomerases showed pronounced antitumor activity. Topoisomerases have been also shown to have a potential for delivering antibacterial compounds or drug candidates. In addition, topoisomerases are involved in the cardiovascular and nervous system diseases. Dong et al. gained a better understanding of the probable binding modes of evodiamine within the human topoisomerase I binding pocket. They also designed and synthesized a series of evodiamine analogues and investigated their structure-activity relationship. Various groups were introduced to the indole nitrogen atom of evodiamine, and the substituted benzoyl groups were found to be favorable for the antitumor activity. The result of the biological activity test showed that the 4-Cl benzoyl derivative was the most active one with IC50 values in the range 0.049–2.6 μM. Figure 5 shows the possible binding mode of evodiamine and 3-(4-chlorobenzoyl) evodiamine in the active site of topoisomerase I-DNA complex.

3.3. Aryl Hydrocarbon Receptor

The AhR is a member of the family of basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) transcription factors. Non-ligand bound AhR is retained in the cytoplasm as an inactive protein complex bound to several co-chaperones. Upon ligand binding to AhR, the chaperones are released, AhR imported into the nucleus and dimerized with AhR nuclear translocator (ARNT), leading to changes in gene transcription. AhR plays a functional role in physiology and toxicology, especially in cellular proliferation and differentiation, the adaptive response, the toxic response, secretion of hormones and immunomodulation. Recently, scientists found that AhR activation seems to be also important for cancer and inflammation, supporting the possibility of targeting the AhR for therapy in inflammation and a number of cancers. Recently, we investigated the interaction between evodiamine and AhR. We observed that a series of hydrophobic residues of AhR are involved in complex formation: Phe285, Phe295, Gly304, Val307, Leu308, Ile325, Cys333, Met348, Val363, and Ser365 (Figure 6). However, there is any hydrogen bond between AhR and evodiamine. Competitive ligand binding assay showed that evodiamine inhibited the specific binding of [3H]-TCDD, the best-characterised AhR agonist, to the AhR with an IC50 value of 44.8 ± 6.5 nM. The corresponding Ki value calculated for evodiamine was 28.4 ± 4.9 nM. AhR binding studies in vitro provided the evidence that evodiamine was able to bind to the AhR as ligand and exhibit antagonistic effects.

4. Pharmacokinetics

Evodiamine is sparingly soluble. Some efforts have been done to improve the bioavailability of evodiamine. Previous studies have revealed that solid dispersions of evodiamine in hard capsules have a greater absorption rate than enriched samples of evodiamine in physical mixture hard capsules. Tan et al. designed a novel evodiamine-phospholipid complex, which has higher bioavailability than evodiamine. The pharmacokinetics of evodiamine were investigated in rats. Recent research indicated that the plasma concentration of evodiamine reached the maximum level within 1 h after oral administration, and 19% of orally administered evodiamine was excreted in urine after 24 h. The main pharmacokinetic parameters were also calculated after oral administration of Wu-Chu-Yu extracts with different purities to rats. Additionally, Lin et al. developed a sensitive and selective liquid chromatography-mass spectrometry method for the determination of evodiamine in rabbit plasma for pharmacokinetic study.

5. Conclusions

This review focuses on potent and diverse bioactivities of evodiamine reported in the recent years. The target-binding properties of evodiamine were also highlighted. Information provided in this manuscript can be useful not only to exploit their biological potential appropriately, but also to develop multi-target drugs of future for treatment of various diseases.

References 136

  1. 1.

    Wang Y., Fan X., Qu H., Gao X., Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional chinese medicine. Curr. Top Med. Chem. 2012;12:1356-1362.

    Not in our library10.2174/156802612801319034

  2. 2.

    Petrelli A., Giordano S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr. Med. Chem. 2008;15:422-432.

    Not in our library10.2174/092986708783503212

  3. 3.

    Tong X.L., Dong L., Chen L., Zhen Z. Treatment of diabetes using traditional Chinese medicine: Past, present and future. Am. J. Chin. Med. 2012;40:877-886.

    Not in our library10.1142/s0192415x12500656

  4. 4.

    Wang S., Wu X., Tan M., Gong J., Tan W., Bian B., Chen M., Wang Y. Fighting fire with fire: Poisonous Chinese herbal medicine for cancer therapy. J. Ethnopharmacol. 2012;140:33-45.

    Not in our library10.1016/j.jep.2011.12.041

  5. 5.

    Chen Y.F. Traditional Chinese herbal medicine and cerebral ischemia. Front Biosci. (Elite Ed.). 2012;4:809-817.

    Not in our library10.2741/e420

  6. 6.

    Liu Z.L., Liu J.P., Zhang A.L., Wu Q., Ruan Y., Lewith G., Visconte D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst. Rev. 2011;7:CD008305.

    Not in our library10.1002/14651858.cd008305.pub2

  7. 7.

    Yue R., Shan L., Yang X., Zhang W. Approaches to target profiling of natural products. Curr. Med. Chem. 2012;19:3841-3855.

    Not in our library10.2174/092986712801661068

  8. 8.

    Zhao J., Yang P., Li F., Tao L., Ding H., Rui Y., Cao Z., Zhang W. Therapeutic effects of astragaloside IV on myocardial injuries: Multi-target identification and network analysis. PLoS One. 2012;7:e44938.

    Not in our library10.1371/journal.pone.0044938

  9. 9.

    Liao J.F., Chiou W.F., Shen Y.C., Wang G.J., Chen C.F. Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components. Chin. Med. 2011;6:6-13.

    Not in our library10.1186/1749-8546-6-6

  10. 10.

    Moon T.C., Murakami M., Kudo I., Son K.H., Kim H.P., Kang S.S., Chang H.W. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm. Res. 1999;48:621-625.

    Not in our library10.1007/s000110050512

  11. 11.

    Choi Y.H., Shin E.M., Kim Y.S., Cai X.F., Lee J.J., Kim H.P. Anti-inflammatory principles from the fruits of Evodia rutaecarpa and their cellular action mechanisms. Arch. Pharm. Res. 2006;29:293-297.

    Not in our library10.1007/bf02968573

  12. 12.

    Kobayashi Y., Nakano Y., Kizaki M., Hoshikuma K., Yokoo Y., Kamiya T. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med. 2001;67:628-633.

    Not in our library10.1055/s-2001-17353

  13. 13.

    Fei X.F., Wang B.X., Li T.J., Tashiro S., Minami M., Xing D.J., Ikejima T. Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci. 2003;94:92-98.

    Not in our library10.1111/j.1349-7006.2003.tb01358.x

  14. 14.

    Kobayashi Y. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 2003;69:425-428.

    Not in our library10.1055/s-2003-39701

  15. 15.

    Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064.

    Not in our library10.1096/fasebj.6.12.1381691

  16. 16.

    Chiou W.F., Sung Y.J., Liao J.F., Shum A.Y., Chen C.F. Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J. Nat. Prod. 1997;60:708-711.

    Not in our library10.1021/np960495z

  17. 17.

    Ko H.C., Wang Y.H., Liou K.T., Chen C.M., Chen C.H., Wang W.Y., Chang S., Hou Y.C., Chen K.T., Chen C.F., et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur. J. Pharmacol. 2007;555:211-217.

    Not in our library10.1016/j.ejphar.2006.10.002

  18. 18.

    Liu Y.N., Pan S.L., Liao C.H., Huang D.Y., Guh J.H., Peng C.Y., Chang Y.L., Teng C.M. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock. 2009;32:263-269.

    Not in our library10.1097/shk.0b013e31819940cb

  19. 19.

    Lin C.R., Amaya F., Barrett L., Wang H., Takada J., Samad T.A., Woolf C.J. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J. Pharmacol. Exp. Ther. 2006;319:1096-1103.

    Not in our library10.1124/jpet.106.105569

  20. 20.

    Ogasawara M., Matsubara T., Suzuki H. Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol. Pharm. Bull. 2001;24:917-920.

    Not in our library10.1248/bpb.24.917

  21. 21.

    Ogasawara M., Matsubara T., Takahashi S., Saiki I., Suzuki H. Anti-invasive and metastatic activities of evodiamine. Biol. Pharm. Bull. 2002;25:1491-1493.

    Not in our library10.1248/bpb.25.1491

  22. 22.

    Wang C., Wang M.W., Tashiro S., Onodera S., Ikejima T. Evodiamine induced human melanoma A375-S2 cell death partially through interleukin 1 mediated pathway. Biol. Pharm. Bull. 2005;28:984-989.

    Not in our library10.1248/bpb.28.984

  23. 23.

    Lee T.J., Kim E.J., Kim S., Jung E.M., Park J.W., Jeong S.H., Park S.E., Yoo Y.H., Kwon T.K. Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Mol. Cancer Ther. 2006;5:2398-2407.

    Not in our library10.1158/1535-7163.mct-06-0167

  24. 24.

    Huang Y.C., Guh J.H., Teng C.M. Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci. 2004;75:35-49.

    Not in our library10.1016/j.lfs.2003.11.025

  25. 25.

    Kan S.F., Yu C.H., Pu H.F., Hsu J.M., Chen M.J., Wang P.S. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J. Cell. Biochem. 2007;101:44-56.

    Not in our library10.1002/jcb.21036

  26. 26.

    Huang D.M., Guh J.H., Huang Y.T., Chueh S.C., Chiang P.C., Teng C.M. Induction of mitotic arrest and apoptosis in human prostate cancer PC-3 cells by evodiamine. J. Urol. 2005;173:256-261.

    Not in our library10.1097/01.ju.0000141587.72429.e3

  27. 27.

    Kang S.F., Huang W.J., Lin L.C., Wang P.S. Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int. J. Cancer. 2004;110:641-651.

    Not in our library10.1002/ijc.20138

  28. 28.

    Liao C.H., Pan S.L., Guh J.H., Chang Y.L., Pai H.C., Lin C.H., Teng C.M. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis. 2005;26:968-975.

    Not in our library10.1093/carcin/bgi041

  29. 29.
    Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpa · 2009
    No notice
  30. 30.

    Zhang Y., Wu L.J., Tashiro S., Onodera S., Ikejima T. Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol. Pharm. Bull. 2003;26:1543-1547.

    Not in our library10.1248/bpb.26.1543

  31. 31.

    Zhang Y., Wu L.J., Tashiro S., Onodera S., Ikejima T. Evodiamine induces tumor cell death through two different pathways: Apoptosis and necrosis. Acta Pharmacol. Sin. 2004;25:83-89.

    Not in our library

  32. 32.

    Zhang Y., Zhang Q.H., Wu L.J., Tashiro S., Onodera S., Ikejima T. A typical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J. Asian Nat. Prod. Res. 2004;6:19-27.

    Not in our library10.1080/1028602031000119772

  33. 33.

    Takada Y., Kobayashi Y., Aggarwal B.B. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 2005;280:17203-17212.

    Not in our library10.1074/jbc.m500077200

  34. 34.

    Chen M.C., Yu C.H., Wang S.W., Pu H.F., Kan S.F., Lin L.C., Chi C.W., Ho L.L., Lee C.H., Wang P.S. Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J. Cell. Biochem. 2010;110:1495-1503.

    Not in our library10.1002/jcb.22716

  35. 35.

    Zhang C., Fan X., Xu X., Yang X., Wang X., Liang H.P. Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells. Anticancer Drugs. 2010;21:766-776.

    Not in our library10.1097/cad.0b013e32833d26a9

  36. 36.

    Yang J., Wu L.J., Tashino S., Onodera S., Ikejima T. Critical roles of reactive oxygen species in mitochondrial permeability transition in mediating evodiamine-induced human melanoma A375-S2 cell apoptosis. Free Radic. Res. 2007;41:1099-1108.

    Not in our library10.1080/10715760701499356

  37. 37.

    Yang J., Wu L.J., Tashiro S., Onodera S., Ikejima T. Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells. Free Radic. Res. 2008;42:1-11.

    Not in our library10.1080/10715760701762407

  38. 38.

    Yang J., Wu L.J., Tashino S., Onodera S., Ikejima T. Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic. Res. 2008;42:492-504.

    Not in our library10.1080/10715760802112791

  39. 39.

    Yang J., Wu L.J., Tashino S., Onodera S., Ikejima T. Protein tyrosine kinase pathway-derived ROS/NO productions contribute to G2/M cell cycle arrest in evodiamine-treated human cervix carcinoma Hela cells. Free Radic. Res. 2010;44:792-802.

    Not in our library10.3109/10715762.2010.481302

  40. 40.

    Wang C., Li S., Wang M.W. Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol. In Vitro. 2010;24:898-904.

    Not in our library10.1016/j.tiv.2009.11.019

  41. 41.

    Wei W.T., Chen H., Wang Z.H., Ni Z.L., Liu H.B., Tong H.F., Guo H.C., Liu D.L., Lin S.Z. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int. J. Biol. Sci. 2012;8:1-14.

    Not in our library10.7150/ijbs.8.1

  42. 42.

    Chao D.C., Lin L.J., Hsiang C.Y., Li C.C., Lo H.Y., Liang J.A., Kao S.T., Wu S.L., Ho T.Y. Evodiamine inhibits 12-O-tetradecanoylphorbol-13-acetate-induced activator protein 1 transactivation and cell transformation in human hepatocytes. Phytother. Res. 2011;25:1018-1023.

    Not in our library10.1002/ptr.3392

  43. 43.

    Shyu K.G., Lin S., Lee C.C., Chen E., Lin L.C., Wang B.W., Tsai S.C. Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci. 2006;78:2234-2243.

    Not in our library10.1016/j.lfs.2005.09.027

  44. 44.

    Ogasawara M., Suzuki H. Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells. Biol. Pharm. Bull. 2004;27:578-582.

    Not in our library10.1248/bpb.27.578

  45. 45.

    Pan X., Hartley J.M., Hartley J.A., White K.N., Wang Z., Bligh S.W. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine. 2012;19:618-624.

    Not in our library10.1016/j.phymed.2012.02.003

  46. 46.

    Chan A.L., Chang W.S., Chen L.M., Lee C.M., Chen C.E., Lin C.M., Hwang J.L. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules. 2009;14:1342-1352.

    Not in our library10.3390/molecules14041342

  47. 47.

    Sheng C., Miao Z., Zhang W. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors. Curr. Med. Chem. 2011;18:4389-4409.

    Not in our library10.2174/092986711797200453

  48. 48.

    Dong G., Sheng C., Wang S., Miao Z., Yao J., Zhang W. Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J. Med. Chem. 2010;53:7521-7531.

    Not in our library10.1021/jm100387d

  49. 49.

    Hu Y., Fahmy H., Zjawiony J.K., Davies G.E. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia. 2010;81:259-268.

    Not in our library10.1016/j.fitote.2009.09.012

  50. 50.

    Shi J., Yan J., Lei Q., Zhao J., Chen K., Yang D., Zhao X., Zhang Y. Intragastric administration of evodiamine suppresses NPY and AgRP gene expression in the hypothalamus and decreases food intake in rats. Brain Res. 2009;1247:71-78.

    Not in our library10.1016/j.brainres.2008.09.091

  51. 51.

    Wang T., Wang Y., Yamashita H. Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway. FEBS Lett. 2009;583:3655-3659.

    Not in our library10.1016/j.febslet.2009.10.046

  52. 52.

    Wang T., Wang Y., Kontani Y., Kobayashi Y., Sato Y., Mori N., Yamashita H. Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: Involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology. 2008;149:358-366.

    Not in our library10.1210/en.2007-0467

  53. 53.

    Wu C.L., Hung C.R., Chang F.Y., Lin L.C., Pau K.Y., Wang P.S. Effects of evodiamine on gastrointestinal motility in male rats. Eur. J. Pharmacol. 2002;457:169-176.

    Not in our library10.1016/s0014-2999(02)02687-0

  54. 54.

    Vincent R.P., Ashrafian H., le Roux C.W. Mechanisms of disease: The role of gastrointestinal hormones in appetite and obesity. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008;5:268-277.

    Not in our library10.1038/ncpgasthep1118

  55. 55.

    Yang H.Y., Li S.Y., Chen C.F. Hypotensive effects of dehydroevodiamine, a quinazolinocarboline alkaloid isolated from Evodia rutaecarpa. Asia Pac. J. Pharmacol. 1988;3:191-195.

    Not in our library

  56. 56.

    Yang M.C., Wu S.L., Kao J.S., Chen C.F. The hypotensive and negative chronotropic effect of dehydroevodiamine. Eur. J. Pharmacol. 1990;182:537-542.

    Not in our library10.1016/0014-2999(90)90052-8

  57. 57.

    Chiou W.F., Chou C.J., Shum A.Y.C., Chen C.F. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: Mode of action. Eur. J. Pharmacol. 1992;215:277-283.

    Not in our library10.1016/0014-2999(92)90039-7

  58. 58.

    Chiou W.F., Liao J.F., Chen C.F. Comparative study on vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J. Nat. Prod. 1996;59:374-378.

    Not in our library10.1021/np960161+

  59. 59.

    Chen C.F., Chen S.M., Lin M.T., Chow S.Y. In vivo and in vitro studies on the mechanism of cardiovascular effects of Wu-Chu-Yu (Evodiae fructus). Am. J. Chin. Med. 1981;9:39-47.

    Not in our library10.1142/s0192415x81000068

  60. 60.

    Hung P.H., Lin L.C., Wang G.J., Chen C.F., Wang P.S. Inhibitory effect of evodiamine on aldosterone release by Zona glomerulosa cells in male rats. Chin. J. Physiol. 2001;44:53-57.

    Not in our library

  61. 61.

    Kobayashi Y., Hoshikuma K., Nakano Y., Yokoo Y., Kamiya T. The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: Possible involvement of vanilloid receptors. Planta Med. 2001;67:244-248.

    Not in our library10.1055/s-2001-12008

  62. 62.

    Rang W.Q., Du Y.H., Hu C.P., Ye F., Tan G.S., Deng H.W., Li Y.J. Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis. Naunyn Schmiedebergs Arch. Pharmacol. 2003;367:306-311.

    Not in our library10.1007/s00210-002-0677-0

  63. 63.

    Yi H.H., Rang W.Q., Deng P.Y., Hu C.P., Liu G.Z., Tan G.S., Xu K.P., Li Y.J. Protective effects of rutaecarpine in cardiac anaphylactic injury is mediated by CGRP. Planta Med. 2004;70:1135-1139.

    Not in our library10.1055/s-2004-835840

  64. 64.

    Yu J., Tan G.S., Deng P.Y., Xu K.P., Hu C.P., Li Y.J. Involvement of CGRP in the inhibitory effect of rutaecarpine on vasoconstriction induced by anaphylaxis in guinea pig. Regul. Pept. 2005;125:93-97.

    Not in our library10.1016/j.regpep.2004.08.001

  65. 65.

    Rang W.Q., Du Y.H., Hu C.P., Ye F., Xu K.P., Peng J., Deng H.W., Li Y.J. Protective effects of evodiamine on myocardial ischemia-reperfusion injury in rats. Planta Med. 2004;70:1140-1143.

    Not in our library10.1055/s-2004-835841

  66. 66.

    Hu C.P., Xiao L., Deng H.W., Li Y.J. The cardioprotection of rutaecarpine is mediated by endogenous calcitonin release-gene peptide through activation of vanilloid receptors in guinea-pig hearts. Planta Med. 2002;68:705-709.

    Not in our library10.1055/s-2002-33794

  67. 67.

    Heo S.K., Yun H.J., Yi H.S., Noh E.K., Park S.D. Evodiamine and rutaecarpine inhibit migration by LIGHT via suppression of NADPH oxidase activation. J. Cell. Biochem. 2009;107:123-133.

    Not in our library10.1002/jcb.22109

  68. 68.

    Mattson M.P. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430:631-639.

    Not in our library10.1038/nature02621

  69. 69.

    Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353-356.

    Not in our library10.1126/science.1072994

  70. 70.

    Kim H.K., Kim M., Kim S., Kim M., Chung J.H. Effects of green tea polyphenol on cognitive and acetylcholinesterase activities. Biosci. Biotechnol. Biochem. 2004;68:1977-1979.

    Not in our library10.1271/bbb.68.1977

  71. 71.

    Lu J.H., Guo J., Yang W.H. Effects of green tea polyphenol on the behaviour of Alzheimer’s disease like mice induced by D-galactose and Abeta25–35. Zhong Yao Cai. 2006;29:352-354.

    Not in our library

  72. 72.

    Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J. Biol. Chem. 2005;280:37377-37382.

    Not in our library10.1074/jbc.m508246200

  73. 73.

    Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Int. 2009;54:111-118.

    Not in our library10.1016/j.neuint.2008.10.008

  74. 74.

    Sehirli O., Tozan A., Omurtag G.Z., Cetinel S., Contuk G., Gedik N., Sener G. Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol. Environ. Saf. 2008;71:301-308.

    Not in our library10.1016/j.ecoenv.2007.08.023

  75. 75.

    Haji A., Momose Y., Takeda R., Nakanishi S., Hiriachi T., Arisawa M. Increased feline cerebral blood flow induced by dehydroevodiamine hydrochloride from Evodia rutaecarpa. J. Nat. Prod. 1994;57:387-389.

    Not in our library10.1021/np50105a009

  76. 76.

    Yuan S.M., Gao K., Wang D.M., Quan X.Z., Liu J.N., Ma C.M., Qin C., Zhang L.F. Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer’s disease. Acta Pharmacol. Sin. 2011;32:295-302.

    Not in our library10.1038/aps.2010.230

  77. 77.

    Park C.H., Kim S.H., Choi W., Lee Y.J., Kim J.S., Kang S.S., Suh Y.H. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med. 1996;62:405-409.

    Not in our library10.1055/s-2006-957926

  78. 78.

    Perrett S., Whitfield P.J. Atanine (3-dimethylallyl-4-methoxy-2-quinolone), an alkaloid with anthelmintic activity from the Chinese medicinal plant, Evodia rutaecarpa. Planta Med. 1995;61:276-278.

    Not in our library10.1055/s-2006-958073

  79. 79.

    Rho T.C., Bae E.A., Kim D.H., Oh W.K., Kim B.Y., Ahn J.S., Lee H.S. Anti-Helicobacter pylori activity of quinolone alkaloids from Evodiae Fructus. Biol. Pharm. Bull. 1999;22:1141-1143.

    Not in our library10.1248/bpb.22.1141

  80. 80.

    Hamasaki N., Ishii E., Tominaga K., Tezuka Y., Nagaoka T., Kadota S., Kuroki T., Yano I. Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro. Microbiol. Immunol. 2000;44:9-15.

    Not in our library10.1111/j.1348-0421.2000.tb01240.x

  81. 81.

    Tominaga K., Higuchi K., Hamasaki N., Hamaguchi M., Takashima T., Tanigawa T., Watanabe T., Fujiwara Y., Tezuke Y., Nagaoka T., et al. In vivo action of novel alkyl methyl quinolone alkaloids against Helicobacter pylori. J. Antimicrob. Chemother. 2002;50:547-552.

    Not in our library10.1093/jac/dkf159

  82. 82.

    Tominaga K., Higuchi K., Hamasaki N., Tanigawa T., Sasaki E., Watanabe T., Fujiwara Y., Oshitani N., Arakawa T., Ishii E., et al. Antibacterial activity of a Chinese herb medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori. Nippon. Rinsho. 2005;63:592-599.

    Not in our library

  83. 83.

    Chiou W.F., Ko H.C., Wei B.L. Evodia rutaecarpa and three major alkaloids abrogate influenza A virus (H1N1)-induced chemokines production and cell migration. Evid. Based Complement. Alternat. Med. 2011;2011:750513.

    Not in our library10.1093/ecam/nep238

  84. 84.

    Caterina M., Julius D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu. Rev. Neurosci. 2001;24:487-517.

    Not in our library10.1146/annurev.neuro.24.1.487

  85. 85.

    Pearce L.V., Petukhov P.A., Szabo T., Kedei N., Bizik F., Kozikowski A.P., Blumberg P.M. Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org. Biomol. Chem. 2004;2:2281-2286.

    Not in our library10.1039/b404506h

  86. 86.

    Peng L., Li Y.J. The vanilloid receptor TRPV-1: Role in cardiovascular and gastrointestinal protection. Eur. J. Pharmacol. 2010;627:1-7.

    Not in our library10.1016/j.ejphar.2009.10.053

  87. 87.

    Matsuda H., Wu T.X., Tanaka T., Linuma M., Kubo M. Antinociceptive activities of 70% methanol extract of Evodiae Fructus (fruit of Evodia rutaecarpavar. bodinieri) and its alkaloidal components. Biol. Pharm. Bull. 1997;20:243-248.

    Not in our library10.1248/bpb.20.243

  88. 88.

    Kano Y., Zong Q.N., Komatsu K. Pharmacological properties of galenical preparation, XIV. Body temperature retaining effect of the Chinese traditional medicine, “goshuyu-to” and component crude drugs. Chem. Pharm. Bull. (Tokyo). 1991;39:690-692.

    Not in our library10.1248/cpb.39.690

  89. 89.

    Tsai T.H., Lee T.F., Chen C.F., Wang L.C. Thermoregulatory effects of alkaloids isolated from Wu-Chu-Yu in afebrile and febrile rats. Pharmacol. Biochem. Behav. 1995;50:293-298.

    Not in our library10.1016/0091-3057(94)00317-c

  90. 90.

    Lin H., Tsai S.C., Chen J.J., Chiao Y.C., Wang S.W., Wang G.J., Chen C.F., Wang P.S. Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism. 1999;48:1532-1535.

    Not in our library10.1016/s0026-0495(99)90241-x

  91. 91.

    Yoshizumi M., Houchi H., Ishimura Y., Hirose M., Kitagawa T., Tsuchiya K., Minakuchi K., Tamaki T. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J. Med. Invest. 1997;44:79-82.

    Not in our library

  92. 92.

    Yu P.L., Chao H.L., Wang S.W., Wang P.S. Effects of evodiamine and rutaecarpine on the secretion of corticosterone by zona fasciculata-reticularis cells in male rats. J. Cell. Biochem. 2009;108:469-475.

    Not in our library10.1002/jcb.22276

  93. 93.

    Yamahara J., Yamada T., Kitani T., Naitoh Y., Fujimura H. Antianoxic action of evodiamine, an alkaloid in Evodia rutaecarpa fruit. J. Ethnopharmacol. 1989;27:185-192.

    Not in our library10.1016/0378-8741(89)90090-1

  94. 94.

    Shin Y.W., Bae E.A., Cai X.F., Lee J.J., Kim D.H. In vitro and in vivo antiallergic effects on the fruits of Evodia rutaecarpa and its constituents. Biol. Pharm. Bull. 2007;30:197-199.

    Not in our library10.1248/bpb.30.197

  95. 95.

    Hu Y., Ehli E.A., Hudziak J.J., Davies G.E. Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region. Pharmacogenomics J. 2012;12:372-378.

    Not in our library10.1038/tpj.2011.24

  96. 96.

    Kobayashi Y., Nakano Y., Hoshikuma K., Yokoo Y., Kamiya T. The bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of Evodia rutaecarpa, on guinea-pig isolated bronchus: Possible involvement on vanilloid receptors. Planta Med. 2000;66:526-530.

    Not in our library10.1055/s-2000-8615

  97. 97.

    Guerrant W., Patil V., Canzoneri J.C., Oyelere A.K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem. 2012;55:1465-1477.

    Not in our library10.1021/jm200799p

  98. 98.

    Wei J., Ching L.C., Zhao J.F., Shyue S.K., Lee H.F., Kou Y.R., Lee T.S. Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis. Acta Physiol. (Oxf.). 2013;207:299-307.

    Not in our library10.1111/apha.12005

  99. 99.

    Devesa I., Planells-Cases R., Fernández-Ballester G., González-Ros J.M., Ferrer-Montiel A., Fernández-Carvajal A. Role of the transient receptor potential vanilloid 1 in inflammation and sepsis. J. Inflamm. Res. 2011;4:67-81.

    Not in our library10.2147/jir.s12978

  100. 100.

    Wanner S.P., Garami A., Pakai E., Oliveira D.L., Gavva N.R., Coimbra C.C., Romanovsky A.A. Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. Cell Cycle. 2012;11:343-349.

    Not in our library10.4161/cc.11.2.18772

  101. 101.

    Palazzo E., Luongo L., de Novellis V., Rossi F., Marabese I., Maione S. Transient receptor potential vanilloid type 1 and pain development. Curr. Opin. Pharmacol. 2012;12:9-17.

    Not in our library10.1016/j.coph.2011.10.022

  102. 102.

    Birerdinc A., Jarrar M., Stotish T., Randhawa M., Baranova A. Manipulating molecular switches in brown adipocytes and their precursors: A therapeutic potential. Prog. Lipid Res. 2012;52:51-61.

    Not in our library10.1016/j.plipres.2012.08.001

  103. 103.

    Luo Z., Ma L., Zhao Z., He H., Yang D., Feng X., Ma S., Chen X., Zhu T., Cao T., et al. TRPV1 activation improves exercise endurance and energy metabolism through PGC-1α upregulation in mice. Cell Res. 2012;22:551-564.

    Not in our library10.1038/cr.2011.205

  104. 104.

    Mori F., Ribolsi M., Kusayanagi H., Monteleone F., Mantovani V., Buttari F., Marasco E., Bernardi G., Maccarrone M., Centonze D. TRPV1 channels regulate cortical excitability in humans. J. Neurosci. 2012;32:873-879.

    Not in our library10.1523/jneurosci.2531-11.2012

  105. 105.

    Lim K.M., Park Y.H. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch. Pharm. Res. 2012;35:393-396.

    Not in our library10.1007/s12272-012-0321-6

  106. 106.

    Santoni G., Caprodossi S., Farfariello V., Liberati S., Gismondi A., Amantini C. Antioncogenic effects of transient receptor potential vanilloid 1 in the progression of transitional urothelial cancer of human bladder. ISRN Urol. 2012;2012:458238.

    Not in our library10.5402/2012/458238

  107. 107.

    Wang Z., Sun L., Yu H., Zhang Y., Gong W., Jin H., Zhang L., Liang H. Binding mode prediction of evodiamine within vanilloid receptor TRPV1. Int. J. Mol. Sci. 2012;13:8958-8969.

    Not in our library10.3390/ijms13078958

  108. 108.

    Giliarov D.A., Shkundina I.S. DNA-topoisomerases and their functions in cell. Mol. Biol. (Mosk.). 2012;46:52-63.

    Not in our library10.1134/s0026893312010074

  109. 109.

    Thai K.M., Bui Q.H., Tran T.D., Huynh T.N. QSAR modeling on benzo[c]phenanthridine analogues as topoisomerase I inhibitors and anti-cancer agents. Molecules. 2012;17:5690-5712.

    Not in our library10.3390/molecules17055690

  110. 110.

    Karki R., Thapa P., Yoo H.Y., Kadayat T.M., Park P.H., Na Y., Lee E., Jeon K.H., Cho W.J., Choi H., et al. Dihydroxylated 2,4,6-triphenyl pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Eur. J. Med. Chem. 2012;49:219-228.

    Not in our library10.1016/j.ejmech.2012.01.015

  111. 111.

    Lee C.H., Hsieh M.Y., Hsin L.W., Chen H.C., Lo S.C., Fan J.R., Chen W.R., Chen H.W., Chan N.L., Li T.K. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles. Biochem. Pharmacol. 2012;83:1208-1216.

    Not in our library10.1016/j.bcp.2012.01.025

  112. 112.

    Sanyal G., Doig P. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin. Drug Discov. 2012;7:327-339.

    Not in our library10.1517/17460441.2012.660478

  113. 113.

    Hiltensperger G., Jones N.G., Niedermeier S., Stich A., Kaiser M., Jung J., Puhl S., Damme A., Braunschweig H., Meinel L., et al. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei. J. Med. Chem. 2012;55:2538-2548.

    Not in our library10.1021/jm101439s

  114. 114.

    Martin E., Thougaard A.V., Grauslund M., Jensen P.B., Bjorkling F., Hasinoff B.B., Tjørnelund J., Sehested M., Jensen L.H. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009;255:72-79.

    Not in our library10.1016/j.tox.2008.10.011

  115. 115.

    Gupta K.P., Swain U., Rao K.S., Kondapi A.K. Topoisomerase IIβ regulates base excision repair capacity of neurons. Mech. Ageing Dev. 2012;133:203-213.

    Not in our library10.1016/j.mad.2012.03.010

  116. 116.

    Burbach K.M., Poland A., Bradfield C.A. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. USA. 1992;89:8185-8189.

    Not in our library10.1073/pnas.89.17.8185

  117. 117.

    Perdew G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J. Biol. Chem. 1988;263:13802-13805.

    Not in our library

  118. 118.

    Kazlauskas A., Poellinger L., Pongratz I. Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J. Biol. Chem. 1999;274:13519-13524.

    Not in our library10.1074/jbc.274.19.13519

  119. 119.

    Meyer B.K., Pray-Grant M.G., Vanden Heuvel J.P., Perdew G.H. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol. Cell. Biol. 1998;18:978-988.

    Not in our library10.1128/mcb.18.2.978

  120. 120.

    Pollenz R.S., Barbour E.R. Analysis of the complex relationship between nuclear export and aryl hydrocarbon receptor-mediated gene regulation. Mol. Cell. Biol. 2000;20:6095-6104.

    Not in our library10.1128/mcb.20.16.6095-6104.2000

  121. 121.

    Hoffman E.C., Reyes H., Chu F.F., Sander F., Conley L.H., Brooks B.A., Hankinson O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 1991;252:954-958.

    Not in our library10.1126/science.1852076

  122. 122.

    Reyes H., Reisz-Porszasz S., Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992;256:1193-1195.

    Not in our library10.1126/science.256.5060.1193

  123. 123.

    Tijet N., Boutros P.C., Moffat I.D., Okey A.B., Tuomisto J., Pohjanvirta R. Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. Mol. Pharmacol. 2006;69:140-153.

    Not in our library10.1124/mol.105.018705

  124. 124.

    Israel D.I., Whitlock J.P. Induction of mRNA specific for cytochrome P1-450 in wild type and variant mouse hepatoma cells. J. Biol. Chem. 1983;258:10390-10394.

    Not in our library

  125. 125.

    Harrigan J.A., Vezina C.M., McGarrigle B.P., Ersing N., Box H.C., Maccubbin A.E., Olson J.R. DNA adduct formation in precision-cut rat liver and lung slices exposed to benzo[a]pyrene. Toxicol. Sci. 2004;77:307-314.

    Not in our library10.1093/toxsci/kfh030

  126. 126.
    SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. · 2012
    Not checked
  127. 127.

    Lee C., Riddick D.S. Aryl hydrocarbon receptor-dependence of dioxin’s effects on constitutive mouse hepatic cytochromes P450 and growth hormone signaling components. Can. J. Physiol. Pharmacol. 2012;90:1354-1363.

    Not in our library10.1139/y2012-099

  128. 128.

    O’Donnell E.F., Kopparapu P.R., Koch D.C., Jang H.S., Phillips J.L., Tanguay R.L., Kerkvliet N.I., Kolluri S.K. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One. 2012;7:e40926.

    Not in our library10.1371/journal.pone.0040926

  129. 129.

    Platten M., Litzenburger U., Wick W. The aryl hydrocarbon receptor in tumor immunity. Oncoimmunology. 2012;1:396-397.

    Not in our library10.4161/onci.19071

  130. 130.

    Monteleone I., Rizzo A., Sarra M., Sica G., Sileri P., Biancone L., MacDonald T.T., Pallone F., Monteleone G. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011;141:237-248.

    Not in our library10.1053/j.gastro.2011.04.007

  131. 131.

    Yu H., Tu Y., Fan X., Wang X., Wang Z., Liang H. Evodiamine as a novel antagonist of aryl hydrocarbon receptor. Biochem. Biophys. Res. Commun. 2010;402:94-98.

    Not in our library10.1016/j.bbrc.2010.09.122

  132. 132.

    Xu H., Zhang T., Yang H., Xiao X., Bian Y., Si D., Liu C. Preparation of evodiamine solid dispersions and its pharmacokinetics. Indian J. Pharm. Sci. 2011;73:276-281.

    Not in our library10.4103/0250-474x.93511

  133. 133.

    Tan Q., Liu S., Chen X., Wu M., Wang H., Yin H., He D., Xiong H., Zhang J. Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech. 2012;13:534-547.

    Not in our library10.1208/s12249-012-9772-9

  134. 134.

    Komatsu K., Wakame K., Kano Y. Pharmacological properties of galenical preparation. XVI. Pharmacokinetics of evodiamine and the metabolite in rats. Biol. Pharm. Bull. 1993;16:935-938.

    Not in our library10.1248/bpb.16.935

  135. 135.

    Jeng K.F., Lin Y.H., Lin L.C., Chou C.J., Tsai T.H., Chen C.F. High-performance liquid chromatographic determination of evodiamine in rat plasma: Application to pharmacokinetic studies. J. Chromatogr. B Biomed. Appl. 1995;668:343-345.

    Not in our library10.1016/0378-4347(95)00090-6

  136. 136.

    Lin C., Pan X., Li W., Ma J., Pan J., Cai J., Wang X., Lin G. Simultaneous determination of evodiamine and rutecarpine in rabbit plasma by LC-ESI-MS and its application to pharmacokinetics. Pharmazie. 2011;66:920-923.

    Not in our library

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.